Core Viewpoint - The biotechnology sector in the STAR Market is showing positive momentum, with significant increases in the performance of key stocks and the STAR Market Biopharmaceutical Index [1][4]. Group 1: Market Performance - As of July 31, 2025, the STAR Market Biopharmaceutical Index rose by 0.57%, with notable stock performances including Teva Biopharma up by 8.39% and Maiwei Biopharma up by 6.68% [1]. - The Jiashi STAR Market Biopharmaceutical ETF recorded a 0.59% increase, indicating active market trading with a turnover rate of 20.3% and a transaction volume of 44.83 million yuan [3]. Group 2: Fund Performance - The Jiashi STAR Market Biopharmaceutical ETF has seen a weekly average transaction volume of 48.48 million yuan, ranking first among comparable funds [3]. - Over the past week, the Jiashi ETF's scale increased by 17.98 million yuan, and its shares grew by 12.50 million, both leading among comparable funds [3]. - The Jiashi ETF's net value increased by 58.87% over the past year, placing it in the top 9.79% among 2,941 index equity funds [3]. Group 3: Key Stocks and Weightings - As of June 30, 2025, the top ten weighted stocks in the STAR Market Biopharmaceutical Index accounted for 50.3% of the index, with leading companies including United Imaging Healthcare and BeiGene [4][6]. - The performance of these stocks varied, with some experiencing declines while others, like Yifang Biopharma, saw increases of 5.85% [6]. Group 4: Industry Outlook - According to Zhongyin Securities, the pharmaceutical sector is witnessing a shift in policy attitudes, with improvements in centralized procurement rules and a growing pipeline of innovative drugs entering the market [6]. - The industry is expected to emerge from a low point, with potential for valuation re-rating as policies and corporate profitability improve [6].

（文章来源：每日经济新闻） 每经AI快讯，7月31日，网络安全概念震荡反弹，数字认证20%涨停，熙菱信息、浩瀚深度、三六零、 锐捷网络、华胜天成、飞乐音响等跟涨。 ...

Group 1 - The A-share cybersecurity sector experienced a volatile rebound, with notable stocks such as Digital Certification hitting a 20% daily limit increase [1] - Other companies that saw gains include Xiling Information, Haohan Depth, 360 Security Technology, Ruijie Networks, Huasheng Tiancai, and Feile Audio [1]

Core Viewpoint - The DSA (Digital Subtraction Angiography) market in China is experiencing significant growth, driven by increasing demand for vascular imaging and intervention, with a competitive landscape featuring both foreign and domestic brands [1][9][20]. Group 1: Overview of DSA Technology - DSA machines utilize X-rays and contrast agents to visualize blood vessels, aiding in the diagnosis of various vascular diseases [2][4]. - The DSA system comprises several components, including X-ray generation, digital imaging, mechanical systems, control systems, and image processing systems [3]. Group 2: Clinical Applications - DSA is crucial for diagnosing cardiovascular diseases, brain vascular diseases, and peripheral vascular diseases, as well as for performing interventional treatments [4][6]. - It serves as the gold standard for coronary artery disease diagnosis and is essential for assessing conditions like aneurysms and vascular blockages [4][6]. Group 3: Market Size and Dynamics - In 2024, the DSA equipment bidding market in China involved 829 procurement units, with a total bid amount of approximately 8.853 billion yuan, averaging 7.484 million yuan per unit [9][11]. - The first half of 2025 saw 411 units bid, totaling around 3.168 billion yuan [9]. Group 4: Competitive Landscape - The DSA market is dominated by foreign brands such as GE Healthcare, Philips, and Siemens, which hold over 90% market share in terms of revenue [13][15]. - Domestic brands like Neusoft and United Imaging are increasingly competitive in the mid-to-low-end market and are making strides into the high-end segment [13][15]. Group 5: Regional Insights - Key regions for DSA equipment procurement include Guangdong, Zhejiang, and Sichuan, which collectively account for 28% of the total bid amount [11]. Group 6: Future Trends - The DSA market is expected to expand further due to an aging population and rising incidence of cardiovascular diseases, alongside government initiatives promoting equipment upgrades [20][22]. - Domestic brands are anticipated to gain more market share, potentially altering the current dominance of foreign brands [20][22].

融券方面，当日融券卖出0.27万股，净卖出0.05万股。 最近三个交易日，28日-30日，联影医疗分别获融资买入0.48亿元、0.31亿元、0.22亿元。 来源：金融界 7月30日，沪深两融数据显示，联影医疗获融资买入额0.22亿元，居两市第868位，当日融资偿还额0.37 亿元，净卖出1471.56万元。 ...

昨天（7月30日），苏州首台冷冻电镜与AI双引擎平台正式面向全球发布。该平台由苏州工业园区 洛加大先进技术研究院牵头打造，通过整合冷冻电镜前沿技术与海量医疗数据，构建起覆盖基础研究到 临床应用的生物医学创新体系，为医药研发与智能诊疗领域注入强劲动能。 在商业模式上，平台采取"双轮驱动"策略：冷冻电镜与生物医学计算平台以硬件销售与软件订阅为 核心，向更多显微研究领域拓展，让AI技术深度介入微观世界的"观察与解读"；医疗大数据平台则聚焦 区域医共体建设，为医疗机构、科研单位及居民提供分级信息服务，推动技术普惠。 此次平台发布，标志着我国在微观探测技术与智能医疗融合领域取得重要突破。依托苏州工业园区 的创新生态，该平台将加速生物医学领域的技术转化与产业升级，为全球医药创新与健康事业发展贡 献"中国方案"。 在科研与医疗应用层面，平台的核心设备与系统各有侧重：200KV冷冻电镜是苏州地区首台提供对 外服务的设备，搭载高性能探测器，可实现原子级分辨率成像，为药物递送机制研究、蛋白质结构解析 等基础科研提供"微观透视"能力；SBDD/AIDD生物医学计算平台则融合结构药物设计与AI药物发现技 术，通过算法精准筛选药物靶点 ...

Group 1 - Company stock price on July 30 was 137.01 yuan, down 0.23% from the previous trading day, with a trading volume of 5.15 billion yuan and 37,402 hands traded, showing a fluctuation of 2.83% [1] - Company specializes in high-end medical imaging equipment, including MRI systems and CT scanners, and is a local listed company in Shanghai [1] - Company showcased multiple AI medical solutions at the 2025 World Artificial Intelligence Conference, including an AI application system for brain and bone metastases developed in collaboration with Sun Yat-sen University Cancer Prevention and Treatment Center, which has been implemented in over 400 hospitals nationwide [1] Group 2 - Main capital outflow on July 30 was 30.417 million yuan [2]

Group 1 - The core concept of the event is the official launch of the "One Pulse Seven Stars" urban brand for Jiading New Town, aiming to create a new pattern of urban integration with high innovation density, high economic density, and high configuration capability [1] - Jiading New Town is structured around the "Hongli River Science and Technology Cultural Waterway," connecting seven key areas, including the Central Activity Area, Jia Bao Smart Bay, Ximen Historical and Cultural District, and others, each showcasing unique advantages and development potential [1] - A series of promotional activities led to the formal release of the "One Pulse Seven Stars • JIA Speed Space" quality carriers, with the signing of the first batch of application scenario projects, including smart water inspection robots and road performance testing projects [1] Group 2 - The unveiling of two digital public service stations, iRIC Intelligent Manufacturing and Robotics International Co-Creation Center and Chuangyuan New Town, aims to provide integrated resources and one-stop digital services to support industrial development in the new town [2] - These service stations focus on empowering enterprises through a new approach involving purchasing computing power, accessing data, building models, and installing software [2]

上海市数字公共服务驿站和上海市数字公共服务驿站（创源新城）也揭牌成立。两家驿站将围绕企 业"买算力、接数据、部模型、装软件"的"开门新四件事"，整合资源，提供梯度化赋能方案和一站式数 字服务，助力新城产业的建设和发展。 上海嘉定区相关负责人表示，嘉定新城将从科技创新、文化传承、产城融合、生态宜居等方面全方位呈 现出魅力与潜力，进一步深化"产城人"融合发展，通过"一脉七星"规划，推动科创策源、文化辐射、公 共服务等功能的能级提升，力争成为长三角城市群中的综合性节点城市和具有较强辐射带动作用的上海 新城标杆。 新华财经上海7月30日电（记者李荣）构建"高创新浓度、高经济密度、高配置能级"的产城融合新格 局。记者30日从2025年上海嘉定新城推介大会上获悉，嘉定新城打响"一脉七星"城市品牌，以"横沥河 科创文化水脉"为城市主轴，串联七大重点区块，形成各有侧重、协同发展的新城建设格局。 据介绍，"一脉七星"空间布局，将串联起七大特色区块：嘉定新城中央活动区凸显城市核心功能聚合效 应；嘉宝智慧湾未来城市实践区勾勒未来城市创新图景；西门历史文化街区展现历史与现代融合之美； 联影小镇突出医疗器械与高端装备产业集聚优势；马东 ...

Core Viewpoint - The integration of AI technology into the healthcare industry is essential for addressing challenges such as global aging, chronic disease burdens, and uneven distribution of medical resources, positioning AI as a systemic solution for sustainable healthcare development [1][3][4]. Group 1: AI Empowerment in Healthcare - AI has transitioned from pilot scenarios to ecosystem restructuring, enhancing efficiency and accessibility in healthcare services [8][11]. - The forum highlighted the need for a new medical data infrastructure to achieve breakthroughs in efficiency, value, and equity [9][11]. - AI applications in healthcare are rapidly evolving, with significant advancements in areas such as pediatric AI pre-consultation, digital imaging in dentistry, and remote dermatology consultations [11][15]. Group 2: Sustainable Innovation in Healthcare - The "2025 Sustainable Innovation Case Recommendation List" was released, showcasing 37 cases from 36 well-known domestic and foreign companies, focusing on urgent industry needs and aligning with the Healthy China 2030 strategy [6][18]. - The list categorizes cases into "International Innovation Localization," "Local Innovation Globalization," and "ESG Innovation Practices," aiming to promote experience sharing and resource integration within the industry [6][18][35]. Group 3: Globalization and Localization Strategies - Multinational companies are deepening localization strategies, evolving from local production to local R&D innovation, while leveraging their technological and resource advantages to foster local innovation [35][41]. - Chinese pharmaceutical companies are increasingly exploring international markets, integrating into the global innovation ecosystem, and ensuring that local innovations benefit a global audience [35][41]. Group 4: ESG and AI in Healthcare - ESG has become a core issue for sustainable development, with a growing focus on integrating AI technology ethics into ESG evaluation dimensions [48]. - Companies are encouraged to disclose AI model training data sources and bias correction mechanisms, ensuring compliance and ethical standards in AI applications [48]. Group 5: Future Directions and Challenges - The healthcare industry faces challenges in high-quality data sample supply and the translation of clinical research into practical applications [11][13]. - The need for a robust AI infrastructure that supports effective business models and enhances traditional services is emphasized, with a focus on data-driven decision-making [50][51].